XORTX Therapeutics Inc.
XRTX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.26% | -19.14% | -2.36% | -3.43% | 0.40% |
| Depreciation & Amortization | -5.46% | -0.38% | 5.71% | -16.18% | -16.32% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.87% | -23.87% | -28.44% | -47.20% | -57.83% |
| Operating Income | 14.87% | 23.87% | 28.44% | 47.20% | 57.83% |
| Income Before Tax | -163.83% | -26.83% | 70.31% | -53.53% | 90.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -163.83% | -26.83% | 70.31% | -53.53% | 90.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.83% | -26.83% | 70.31% | -53.53% | 90.09% |
| EBIT | 14.87% | 23.87% | 28.44% | 47.20% | 57.83% |
| EBITDA | -0.43% | 12.04% | 19.11% | 40.31% | 58.56% |
| EPS Basic | -1,213.33% | -8.07% | 79.15% | -21.23% | 99.12% |
| Normalized Basic EPS | -1,207.08% | -8.02% | 79.15% | -21.24% | 99.11% |
| EPS Diluted | -1,223.33% | -8.16% | 79.02% | -20.48% | 99.12% |
| Normalized Diluted EPS | -1,207.08% | -8.02% | 79.15% | -21.24% | 99.11% |
| Average Basic Shares Outstanding | 52.97% | 46.88% | 52.15% | 45.25% | 36.17% |
| Average Diluted Shares Outstanding | 52.97% | 46.88% | 52.15% | 45.25% | 36.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |